-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on LifeMD, Lowers Price Target to $6

Benzinga·11/13/2026 17:05:07
Listen to the news
Mizuho analyst Steven Valiquette maintains LifeMD (NASDAQ:LFMD) with a Outperform and lowers the price target from $7 to $6.